Plant Healthcare sugarcane in Brazil demonstration plot yield increase of 20% or more

Jeff Tweedy, Commercial Head, Americas for Plant Health Care, said: “We are very encouraged by the support we are receiving from Coplacana in promoting H2Copla in the field and have high expectations for future sales. The Company is now developing Harpin αβ in other crops. In 2017/18, we had most encouraging preliminary results in coffee, with both yield and quality improvements. We are now examining routes to market for Harpin αβ in this crop, with a view to launching for the 2019-2020 growing season. We see coffee as being at least as valuable a crop for the Company as sugarcane.”

Plant Health Care (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, provided the following update on Harpin αβ launch in Brazil.

Highlights

– Harpin αβ applied in sugarcane in Brazil; demonstration plot yield increase of 20% or more.

– Harpin αβ was launched in Brazil sugarcane in February 2018 through Coplacana under the brand name H2Copla. Grower feedback has been strong.

– Since the launch of H2Copla in February 2018, the product has generated revenue of $400k. The Company expects to generate at least as much revenue from H2Copla in the second half of 2018.

– The Company is now planning for the launch of Harpin αβ in coffee, which has similar potential to sugarcane.

With 10 million hectares planted, Brazil sugarcane is an important target for Plant Health Care. The Company has been developing Harpin αβ for use in this crop. Trials have been conducted in both ratoon cane (i.e. cane which grows back after harvest) and newly planted cane (normal practice is to take five crops from ratton cane, then plant again). Trials conducted on behalf of the Company in 2018 showed that single applications of a low dose (100 g per Ha) at six to eight weeks after harvest, significantly increased the yield of ratoon cane (10-29%) in ratoon cane. Moreover, it is possible that the ratoon crop may be extended from five to six years, which is a material cost reduction, especially when sugar prices are low. Trials also indicated that newly planted cane responds well to applications of Harpin αβ.

Based on these promising results, as announced on 16 July 2018, the Company launched a Harpin αβ product with Coplacana, a leading sugarcane co-operative in Brazil, for their exclusive use of the H2Copla brand in sugarcane. Coplacana services more than 70% of the sugarcane hectares in Sao Paolo state, where more than 5 million hectares of the crop are grown. Demonstration trials with Coplacana have shown impressive results, with an average yield increase of over 20%.

H2Copla was launched in February 2018 and the product has received very positive grower feedback. The launch quantities have been largely sold and the Company expects to make further sales during the second half of 2018. We confidently expect sales in Brazilian sugarcane to build in the second half of 2018 and over the coming years.

Arnaldo Bortoletto, President of Coplacana, said “We continue to have excellent field results with H2Copla, with good grower feedback and we expect strong demand for H2Copla in the second half of 2018”.

 

 

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Plant Health Care Plc

    More articles like this

    Plant Health Care Plc

    Plant Health Care appoint new Board directors

    Plant Health Care (LON:PHC) has announced three new Board appointments with effect from 1st November 2019. Mr Guy van Zwanenberg FCA will join the PHC Board as a Non-executive Director. He will take over as Chair of the

    Plant Health Care Plc

    Plant Health Care Progress with PREtec field trials in Brazil

    Plant Health Care (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, has today provided the following update in relation to the 2018/19 field trials of the PREtec peptide PHC279 for the

    Plant Health Care Plc

    Plant Health Group plc New Distribution Agreement for Harpin αß

    Plant Health Care plc (LON:PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced a new distribution agreement with Wilbur-Ellis Company LLC, a leading U.S. agriculture distributor, for exclusive access to

    Path Investments Plc

    Path Investments plc Update on Heads of Agreement

    Path Investments plc (LON: PATH) today provided an update regarding the Heads of Agreement with ARC Marlborough Pty Limited (“ARC”) in relation to the proposed acquisition of ARC by the Company (the “Proposed Transaction”) announced on

    Plant Health Care Plc

    Plant Health Care Made exciting progress in 2018

    Chris Richards, Plant Health Care Interim CEO, commented: “Plant Health Care continued to make exciting progress in 2018, in spite of recently announced set-backs. The launch of our new corn product in the US holds great

    Plant Health Care Plc

    Plant Health Care Plc ProAct® Wins Top Industry Award

    Chris Richards, Executive Chairman and Interim CEO of Plant Health Care noted: “This award is recognition that Plant Health Care, as a science-based company, can bring new benefits to growers with low toxicity, biological products. We

    Plant Health Care Plc

    Plant Health Care to present at Mello London

    Plant Health Care (LON: PHC), a leading provider of novel patent-protected biological products to global agriculture markets, today announced that the Company will be presenting at the Mello London investor conference on Tuesday 27 November 2018